Mallinckrodt Stock Forecast, Price & News

Wall Street analysts have given Mallinckrodt a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mallinckrodt wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Mallinckrodt plc (NYSE:MNK) released its quarterly earnings data on Tuesday, August, 4th. The company reported $1.89 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.34 by $0.55. The business had revenue of $700.90 million for the quarter, compared to the consensus estimate of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 34.26% and a negative net margin of 89.94%. The company's revenue was down 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.53 EPS.
View Mallinckrodt's earnings history.

Some companies that are related to Mallinckrodt include RenovoRx (RNXT), Synthetic Biologics (SYN), Regulus Therapeutics (RGLS), Merrimack Pharmaceuticals (MACK), Cellectar Biosciences (CLRB), Lotus Pharmaceuticals (LTUS), Rockwell Medical (RMTI), Acasti Pharma (ACST), Diffusion Pharmaceuticals (DFFN), FSD Pharma (HUGE), Reviva Pharmaceuticals (RVPH), Acerus Pharmaceuticals (ASPCF), Indaptus Therapeutics (INDP), Enveric Biosciences (ENVB) and Cyclacel Pharmaceuticals (CYCC).
View all of MNK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD).

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

One share of MNK stock can currently be purchased for approximately $0.19.

Mallinckrodt has a market capitalization of $16.37 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis.

Mallinckrodt employs 3,400 workers across the globe.

The official website for Mallinckrodt is www.mallinckrodt.com.

Mallinckrodt is headquartered at COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15.

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected].